ATE144503T1 - Thiazolidin-2,4-dionderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen - Google Patents

Thiazolidin-2,4-dionderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen

Info

Publication number
ATE144503T1
ATE144503T1 AT92402308T AT92402308T ATE144503T1 AT E144503 T1 ATE144503 T1 AT E144503T1 AT 92402308 T AT92402308 T AT 92402308T AT 92402308 T AT92402308 T AT 92402308T AT E144503 T1 ATE144503 T1 AT E144503T1
Authority
AT
Austria
Prior art keywords
thiazolidine
production
pharmaceutical compositions
compositions containing
dione derivatives
Prior art date
Application number
AT92402308T
Other languages
English (en)
Inventor
De Guillaume Nanteuil
Jacques Duhault
Denis Ravel
Yolande Herve
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adir filed Critical Adir
Application granted granted Critical
Publication of ATE144503T1 publication Critical patent/ATE144503T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
AT92402308T 1991-08-20 1992-08-20 Thiazolidin-2,4-dionderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen ATE144503T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9110430A FR2680512B1 (fr) 1991-08-20 1991-08-20 Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.

Publications (1)

Publication Number Publication Date
ATE144503T1 true ATE144503T1 (de) 1996-11-15

Family

ID=9416269

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92402308T ATE144503T1 (de) 1991-08-20 1992-08-20 Thiazolidin-2,4-dionderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen

Country Status (13)

Country Link
US (3) US5266582A (de)
EP (1) EP0528734B1 (de)
JP (1) JPH0730055B2 (de)
AT (1) ATE144503T1 (de)
AU (1) AU645709B2 (de)
CA (1) CA2076444A1 (de)
DE (1) DE69214755T2 (de)
DK (1) DK0528734T3 (de)
ES (1) ES2095432T3 (de)
FR (1) FR2680512B1 (de)
GR (1) GR3022116T3 (de)
NZ (1) NZ244021A (de)
ZA (1) ZA926276B (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005119252A2 (en) * 2004-05-26 2005-12-15 Arena Pharmaceuticals, Inc. Modulators of gpr35 for the treatment of metabolic-related disorders
US5498621A (en) * 1992-05-01 1996-03-12 Pfizer Inc. Oxazolidinedione hypoglycemic agents
ZA936492B (en) * 1992-09-10 1995-03-02 Lilly Co Eli Compounds useful as hypoglycemic agents and for treating Alzheimer's disease.
US5466610A (en) * 1993-09-07 1995-11-14 Eli Lilly And Company Immunoassays for insulin sensitivity enhancers, insulin sensitivity enhancer antibodies, and non-thiazolidinedione insulin sensitivity enhancer compositions
CZ283339B6 (cs) * 1993-09-15 1998-03-18 Sankyo Company Limited Použití thiazolidinových derivátů pro výrobu léčivého přípravku pro léčení zhoršené tolerance glukosy pro zabránění nebo zpoždění nástupu diabetes mellitus nezávislé na inzulinu
CN1083715C (zh) * 1994-02-10 2002-05-01 史密丝克莱恩比彻姆有限公司 胰岛素敏化物治疗肾病的应用
CA2145257A1 (en) * 1994-03-23 1995-09-24 Takashi Fujita Thiazolidine and oxazolidine derivatives, their preparation and their medical use
CZ289317B6 (cs) * 1994-04-11 2002-01-16 Sankyo Company Limited Heterocyklická sloučenina, farmaceutický prostředek ji obsahující a její pouľití
CZ261095A3 (en) * 1994-10-07 1996-04-17 Sankyo Co Oxime derivatives, process of their preparation, pharmaceutical composition containing thereof and their use
US5925656A (en) * 1995-04-10 1999-07-20 Dr. Reddy's Research Foundation Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
IL118474A (en) * 1995-06-01 2001-08-08 Sankyo Co Benzimideol derivatives and pharmaceutical preparations containing them
US6147101A (en) * 1995-06-02 2000-11-14 Kyorin Pharmaceutical Co., Ltd. N-benzyldioxothiazolidylbenzamide derivatives and process for producing the same
JP3144624B2 (ja) * 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
US6001862A (en) * 1995-06-02 1999-12-14 Kyorin Pharameuticals Co., Ltd. N-benzyldioxothiazolidylbenzamide derivatives and processes for preparing the same
JPH09136877A (ja) * 1995-06-16 1997-05-27 Takeda Chem Ind Ltd 複素環化合物、その製造法及び用途
ATE236154T1 (de) * 1995-07-31 2003-04-15 Shionogi & Co Pyrrolydin-derivate mit einer phospholipase a2 inhibierenden wirkung
US5889025A (en) * 1996-05-06 1999-03-30 Reddy's Research Foundation Antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5801173A (en) * 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
ZA973848B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US6372750B2 (en) * 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
US6114526A (en) * 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
USRE39266E1 (en) 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
KR100579765B1 (ko) 1996-07-01 2006-12-28 닥터 레디스 레보러터리즈 리미티드 신규헤테로고리형화합물의제조방법,이를함유하는약제조성물및당뇨병및이와관련된질병의치료에있어서그의용도
CN1221417A (zh) * 1996-07-26 1999-06-30 雷迪博士研究基金会 具有抗糖尿病、降低血脂、抗高血压性能的噻唑烷二酮化合物,其制备方法及其药物组合物
TW577875B (en) * 1997-01-31 2004-03-01 Shionogi & Co Pyrrolidine derivatives with inhibitory activity for phospholipase A2
EP0894089B9 (de) * 1997-05-02 2003-04-02 Dr. Reddy's Laboratories Ltd. Neue heterozyklische verbindungen mit antidiabetischen, hypolipiddaemischen und blutdrucksenkenden eigenschaften, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die diese enthalten
EP0981526B1 (de) * 1997-05-02 2004-02-25 Dr. Reddy's Laboratories Ltd. Neue antidiabetische verbindungen mit hypolipidimischen und antihypertensiven eigenschaften, verfahren zu ihrer herstellung und ihre enthaltenden arzneimittel
AU7684798A (en) * 1997-05-30 1998-12-30 Texas Biotechnology Corporation Compounds that inhibit the binding of vascular endothelial growth factor to its receptors
BR9810142A (pt) 1997-06-18 2000-08-08 Smithkline Beecham Plc Tratamento de diabete com tiazolidinadiona e sulfonil-uréia
WO2000018746A1 (en) * 1998-09-30 2000-04-06 Roche Diagnostics Gmbh Thiazolidine derivatives for the treatment and prevention of metabolic bone disorders
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
EP1131070B1 (de) 1998-11-12 2008-09-03 SmithKline Beecham plc Arzneimittel zur gesteuerten freisetzung eines insulin sensibilisators und metformin
DZ2937A1 (fr) * 1998-11-12 2004-03-15 Smithkline Beecham Plc Compositions nouvelles de sensibilidants à l'insuline.
CZ300691B6 (cs) 1999-04-07 2009-07-15 Sankyo Company, Limited Derivát aminu, jeho použití a farmaceutický prostredek jej obsahující
ES2248242T3 (es) * 2000-04-21 2006-03-16 Pfizer Products Inc. Ligandos de receptores tiroideos.
US6620830B2 (en) 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
US6768008B2 (en) * 2000-04-24 2004-07-27 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6784199B2 (en) * 2000-09-21 2004-08-31 Aryx Therapeutics Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis in mammals
US6680387B2 (en) 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
JP2003531200A (ja) * 2000-04-24 2003-10-21 アリックス セラピューティクス 糖尿病、高脂血症、高コレステロール血症、およびアテローム性動脈硬化症の治療のための材料と方法
US6958355B2 (en) * 2000-04-24 2005-10-25 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US6452014B1 (en) * 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
US20060047000A1 (en) * 2001-04-24 2006-03-02 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
ITRM20020016A1 (it) * 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi fenil(alchil)carbossilici e derivati fenilalchileterociclici dionici, loro uso come medicamenti ad attivita' ipoglicemizza
US20050107387A1 (en) * 2003-05-13 2005-05-19 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
EP2032570A4 (de) * 2006-06-13 2010-10-27 Merck Frosst Canada Ltd Azacyclopentanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase
US20120094959A1 (en) 2010-10-19 2012-04-19 Bonnie Blazer-Yost Treatment of cystic diseases
AP2014007805A0 (en) 2011-12-28 2014-07-31 Cytokinetics Inc The Regents Of The University Of California Substituted benzaldehyde compounds and methods fortheir use in increasing tissue oxygenation
US9012450B2 (en) 2011-12-28 2015-04-21 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
SG10201802911RA (en) 2013-03-15 2018-05-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
EP2970308B1 (de) 2013-03-15 2021-07-14 Global Blood Therapeutics, Inc. Verbindungen und verwendungen davon zur modulation von hämoglobin
MX2015011769A (es) 2013-03-15 2016-06-02 Global Blood Therapeutics Inc Compuestos y sus usos para modular la hemoglobina.
SG11201507351PA (en) * 2013-03-15 2015-10-29 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
PT3102208T (pt) 2014-02-07 2021-04-05 Global Blood Therapeutics Inc Polimorfos cristalinos da base livre de 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3 il)metoxi)benzaldeído
US10034868B2 (en) 2014-11-04 2018-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
BR112018011272A2 (pt) 2015-12-04 2018-11-21 Global Blood Therapeutics Inc regimes de dosagem para 2-hidróxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metóxi)benzaldeído
TWI752307B (zh) 2016-05-12 2022-01-11 美商全球血液治療公司 新穎化合物及製造化合物之方法
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
EP3860975B1 (de) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulatoren von hämoglobin zur behandlung von sichelzellenanämie

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
WO1985004170A1 (en) * 1984-03-21 1985-09-26 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, process for their preparation, and medicinal composition containing same
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
JPH0653738B2 (ja) * 1985-02-26 1994-07-20 三共株式会社 チアゾリジン誘導体
DK173350B1 (da) * 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
WO1986007056A1 (en) * 1985-05-21 1986-12-04 Pfizer Inc. Hypoglycemic thiazolidinediones
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
US4873255A (en) * 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use

Also Published As

Publication number Publication date
JPH0730055B2 (ja) 1995-04-05
ZA926276B (en) 1993-03-02
FR2680512A1 (fr) 1993-02-26
EP0528734A1 (de) 1993-02-24
US5296605A (en) 1994-03-22
ES2095432T3 (es) 1997-02-16
US5330999A (en) 1994-07-19
NZ244021A (en) 1995-01-27
US5266582A (en) 1993-11-30
FR2680512B1 (fr) 1995-01-20
GR3022116T3 (en) 1997-03-31
DE69214755T2 (de) 1997-05-07
EP0528734B1 (de) 1996-10-23
JPH05213913A (ja) 1993-08-24
AU645709B2 (en) 1994-01-20
DK0528734T3 (da) 1997-04-07
DE69214755D1 (de) 1996-11-28
CA2076444A1 (fr) 1993-02-21
AU2110892A (en) 1993-02-25

Similar Documents

Publication Publication Date Title
ATE144503T1 (de) Thiazolidin-2,4-dionderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
DE69202313D1 (de) Naphthylethylharnstoff und Naphthylethylthioharnstoff Verbindungen, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten.
DE69622992T2 (de) Substituierte heterocyclische verbindungen, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
ATE145904T1 (de) Isochinolin-5-yl-sulfonsäureamide, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten
ATE129503T1 (de) Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien.
ATE7699T1 (de) Cephalosporinderivate, sie enthaltende pharmazeutische praeparate und verfahren zu ihrer herstellung.
ATE24488T1 (de) 3-hydroxypyrrolidin-2-on-derivate, verfahren und zwischenprodukte zu deren herstellung und diese enthaltende arzneimittel.
AU3860893A (en) New benzimidazole compounds, a process for their preparation and pharmaceutical compositions containing them
ATE160338T1 (de) Alpha aminosäurederivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE172976T1 (de) 3-aminochroman-spiroderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE107298T1 (de) 3-aminochroman-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE118212T1 (de) 1-(alkoxybenzyl)piperazineamide, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE69013173D1 (de) Bisarylalkenderivate, Verfahren zu deren Herstellung und pharmazeutische Zusammensetzung, die sie enthalten.
ATE144510T1 (de) N-(isochinolein-5-yl)-sulfonyl azazykloalkane, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
DE3881484T2 (de) Optisch aktive Produkte von 20,21-Dinoreburnamenin-Derivaten, Verfahren zur Herstellung, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammenstellungen.
ES2062214T3 (es) Derivados de aminooligohidroxi inhibidores de renina.
DE69215511T2 (de) Gem-diphosphonsäure-nitrosocarbamoylderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zubereitungen
ATE106873T1 (de) Pyridylsulfonylharnstoff- und pyridylsulfonylthioharnstoff-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee